Back to Authors

Agarwal, Amit

https://orcid.org/0000-0002-7342-4969

Mayo Clinic

Bristol-Myers Squibb (United States)

Citations 16

Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Chanan‐Khan, Asher , Agarwal, Amit , Kumar, Shaji , Diehl, Susan, Cordero, Jaclyn, Munasinghe, Wijith, Zhu, Ming , Maciag, Paulo , Verdugo, Maria E., Moreau, Philippe , Roberts, Andrew W. , Facon, Thierry T.F. , Touzeau, Cyrille , Ross, Jeremy A. , Salem, Ahmed Hamed , Leverson, Joel D. , Harrison, Simon J

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8011-8011

10.1200/jco.2016.34.15_suppl.8011 Get It

Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.
Rifkin, Robert M. , Gasparetto, Cristina, Toomey, Kathleen, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Srinivasan, Shankar , YoussefAgha, Ahmed, Ung, Brian , Kitali, Amani, Flick, E. Dawn, Agarwal, Amit , Abonour, Rafat , Jagannath, Sundar , Gasparetto, Cristina , Hardin, James W. , Wagner, Lynne I. , Ailawadhi, Sikander

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8041-8041

10.1200/jco.2018.36.15_suppl.8041 Get It

Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.
Gasparetto, Cristina, Rifkin, Robert M. , Terebelo, Howard R. , Toomey, Kathleen, Durie, Brian G.M. , Narang, Mohit , Flick, E. Dawn, Kotey, Stanley, Srinivasan, Shankar , Kitali, Amani, Agarwal, Amit , Abonour, Rafat , Gasparetto, Cristina , Hardin, James W. , Jagannath, Sundar , Wagner, Lynne I. , Ailawadhi, Sikander

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8037-8037

10.1200/jco.2018.36.15_suppl.8037 Get It

Maintenance (MT) treatment (Tx) after lenalidomide, bortezomib, and dexamethasone (RVD) induction and stem cell transplant (SCT) in high-risk (HR) patients (pts) with newly diagnosed multiple myeloma (NDMM): A real-world analysis.
Parikh, Kejal , Ung, Brian , Ni, Quanhong, Agarwal, Amit , Fonseca, Rafaël

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e20041-e20041

10.1200/jco.2018.36.15_suppl.e20041 Get It

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).
Holstein, Sarah A. , Larkins, Gail, Chung, Weiyuan, Srinivasan, Shankar , Agarwal, Amit , Ailawadhi, Sikander , McCarthy, Philip L. , Lonial, Sagar

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8050-8050

10.1200/jco.2018.36.15_suppl.8050 Get It

Denosumab Chemotherapy for Recurrent Giant-Cell Tumor of Bone: A Case Report of Neoadjuvant Use Enabling Complete Surgical Resection
Agarwal, Amit , Larsen, Brandon T. , Buadu, Lawrence Danso, Dunn, Jack , Crawford, Russell M. , Bishop, Maria C., Daniel, Jonathan C.

Case Reports in Oncological Medicine | July 30, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-4

10.1155/2013/496351 Get It

Giant-cell tumor of the bone (GCTB) is a rare neoplasm that affects young adults. The tumor is generally benign but sometimes can be locally aggressive. There are no standardized approaches to the treatment of GCTB. Recently, the RANKL inhibitor denosumab has shown activity in this tumor type. We present the case of a young female who presented with locally advanced disease and was successfully managed with the neoadjuvant use of denosumab allowing for surgical resection of the tumor that was previously deemed unresectable. Following surgery, the patient is being managed with continued use of denosumab as ‘maintenance,’ and she continues to be free of disease. Our case highlights a novel approach for the management of locally advanced and aggressive giant cell tumor of the bone.